Urogen Pharma (NASDAQ:URGN) Shares Gap Down – What’s Next?

Shares of Urogen Pharma (NASDAQ:URGN – Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $26.18, but opened at $24.00. Urogen Pharma shares last traded at $25.5580, with a volume of 311,241 shares trading hands.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Guggenheim lowered their target price on Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. TD Cowen lifted their price target on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Jefferies Financial Group reissued a “buy” rating and issued a $56.00 price target on shares of Urogen Pharma in a report on Thursday, September 10th. Oppenheimer set a $60.00 price objective on Urogen Pharma in a research report on Thursday, November 5th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a research note on Thursday, October 15th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $53.38.

View Our Latest Stock Analysis on URGN

Urogen Pharma Stock Performance

The firm’s 50 day moving average price is $37.00 and its 200-day moving average price is $31.67. The firm has a market capitalization of $1.38 billion, a PE ratio of -21.42 and a beta of 1.68.

Urogen Pharma (NASDAQ:URGN – Get Free Report) last announced its quarterly earnings results on Wednesday, November 4th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.14). The company had revenue of $89.00 million during the quarter, compared to analysts’ expectations of $89.92 million. On average, equities research analysts expect that Urogen Pharma will post -0.36 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Chris Degnan sold 2,202 shares of the company’s stock in a transaction that occurred on Thursday, October 8th. The stock was sold at an average price of $36.69, for a total transaction of $80,791.38. Following the completion of the transaction, the chief financial officer directly owned 4,561 shares of the company’s stock, valued at $167,343.09. This represents a 32.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Mark Schoenberg sold 871 shares of the stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the transaction, the insider owned 59,882 shares in the company, valued at $2,570,135.44. This trade represents a 1.43% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 65,269 shares of company stock worth $3,037,646 over the last three months. 4.80% of the stock is currently owned by corporate insiders.

Institutional Trading of Urogen Pharma

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. purchased a new stake in shares of Urogen Pharma during the second quarter worth $117,814,000. Jefferies Financial Group Inc. acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $80,947,000. Bank of America Corp DE acquired a new stake in shares of Urogen Pharma in the second quarter valued at about $17,506,000. Rice Hall James & Associates LLC purchased a new position in shares of Urogen Pharma in the second quarter worth about $11,064,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Urogen Pharma in the second quarter worth about $9,288,000. Hedge funds and other institutional investors own 91.29% of the company’s stock.

About Urogen Pharma

(Get Free Report)

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.

Further Reading

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.